Table 1.
Characteristics | PDAC |
---|---|
(n = 293) | |
Age, years | |
Median | 64 |
Range | 24–82 |
Sex | |
male - no. (%) | 163 (56%) |
female - no. (%) | 130 (44%) |
Arm | |
Gemcitabine - no. (%) | 149 (51%) |
Gemcitabine + Erlotnib - no. (%) | 144 (49%) |
Karnofsky | |
60 - no. (%) | 1 (>1%) |
70 - no. (%) | 10 (3%) |
80 - no. (%) | 75 (26%) |
90 - no. (%) | 112 (38%) |
100 - no. (%) | 95 (32%) |
Grading | |
G1 - no. (%) | 7 (2%) |
G2 - no. (%) | 180 (61%) |
G3 - no. (%) | 96 (33%) |
unknown - no. (%) | 10 (4%) |
T-Stage | |
T1 - no. (%) | 9 (3%) |
T2 - no. (%) | 30 (10%) |
T3 - no. (%) | 251 (86%) |
T4 - no. (%) | 3 (1%) |
N-Stage | |
N0 - no. (%) | 106 (36%) |
N1 - no. (%) | 187 (64%) |
Postoperative CA 19–9, kU/L | |
Median (range) | 19,5 (1–5816) |
≤ 100 - no. (%) | 223 (76%) |
101–500 - no. (%) | 29 (10%) |
> 500 - no. (%) | 12 (4%) |
unknown - no. (%) | 29 (10%) |